Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 56.7%.

  • Viridian Therapeutics, Inc.\DE's EBIT Margin rose 970130700.0% to 56.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 463.52%, marking a year-over-year increase of 932590000.0%. This contributed to the annual value of 99018.21% for FY2024, which is 179831800.0% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's EBIT Margin stood at 56.7%, which was up 970130700.0% from 142356.0% recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year EBIT Margin high stood at 56.7% for Q3 2025, and its period low was 142356.0% during Q2 2025.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's EBIT Margin averaged around 57473.73%, with its median value being 71144.44% (2023).
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's EBIT Margin crashed by -707779500bps in 2023, and later skyrocketed by 970130700bps in 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's EBIT Margin (Quarter) stood at 13589.25% in 2021, then tumbled by -244bps to 46729.52% in 2022, then plummeted by -112bps to 99275.0% in 2023, then decreased by -22bps to 121488.89% in 2024, then soared by 100bps to 56.7% in 2025.
  • Its last three reported values are 56.7% in Q3 2025, 142356.0% for Q2 2025, and 130369.44% during Q1 2025.